Targets › CHRM1
17 programs from 16 companies in 47 trials: 24 Phase 3, 12 Phase 2, 8 Phase 1, 3 Phase 4; Psychiatry, Ophthalmology, Neurology; next expected readout Dec 2026.
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover. (UniProt, P11229)
Open in Phaseline: the race on CHRM1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Southern College of Optometry | Pilocarpine Muscarinic acetylcholine receptor M3 agonist; Muscarinic acetylcholine receptor M1 agonist | CHRM3, CHRM1 | Phase 4 | Presbyopia | – |
| Hospital Sirio-Libanes | Biperiden Hydrochloride Muscarinic acetylcholine receptor M1 antagonist | CHRM1 | Phase 3 | Brain Injury Traumatic Moderate | Dec 2026 |
| Bristol-Myers Squibb | Xanomeline Muscarinic acetylcholine receptor M4 agonist; Muscarinic acetylcholine receptor M1 agonist | CHRM4, CHRM1 | Phase 3 | Alzheimer Disease; Alzheimer's Disease; Healthy Volunteers; SCHIZOPHRENIA 1 (Disorder) | Mar 2027 |
| Ocus Innovation Ireland | Atropine Muscarinic acetylcholine receptor M3 antagonist; Muscarinic acetylcholine receptor M1 antagonist; Muscarinic acetylcholine receptor M2 antagonist | CHRM3, CHRM1, CHRM2 | Phase 3 | Myopia | Dec 2027 |
| Oslo University Hospital | Buscopan 20 MG/ML Injectable Solution Anticholinergic agent that reduces smooth muscle spasms | CHRM1, CHRM3 | Phase 3 | Labor Complication | Dec 2027 |
| Montefiore Medical Center | Pilocarpine Muscarinic acetylcholine receptor M3 agonist; Muscarinic acetylcholine receptor M1 agonist | CHRM3, CHRM1 | Phase 3 | Glaucoma | Jun 2028 |
| Sherief Abd-Elsalam | orphenadrine Anticholinergic drug with CNS and peripheral activity; used for muscle spasms and pain | CHRM1, CHRM2, CHRM3 | Phase 3 | Liver Cirrhosis | Dec 2028 |
| Bristol-Myers Squibb | Xanomeline (BMS-986519) Muscarinic acetylcholine receptor M4 agonist; Muscarinic acetylcholine receptor M1 agonist | CHRM4, CHRM1 | Phase 3 | Schizophrenia | Mar 2030 |
| Zhaoke (Guangzhou) Ophthalmology Pharmaceutical | Atropine Muscarinic acetylcholine receptor M3 antagonist; Muscarinic acetylcholine receptor M1 antagonist; Muscarinic acetylcholine receptor M2 antagonist | CHRM3, CHRM1, CHRM2 | Phase 3 | Myopia; Achalasia; Progressive Myopia; Focus on Axial Length … | – |
| Belfast Health and Social Care Trust | Atropine Sulfate Muscarinic acetylcholine receptor M3 antagonist; Muscarinic acetylcholine receptor M1 antagonist; Muscarinic acetylcholine receptor M2 antagonist | CHRM3, CHRM1, CHRM2 | Phase 2 | Myopia | Feb 2027 |
| Novartis | Glycopyrronium bromide Muscarinic acetylcholine receptor M3 antagonist; Muscarinic acetylcholine receptor M1 antagonist | CHRM3, CHRM1 | Phase 2 | Asthma; Post-Dural Puncture Headache | Jul 2027 |
| ACADIA Pharmaceuticals | ACP-211 Muscarinic M1 receptor positive allosteric modulator | CHRM1 | Phase 2 | Major Depressive Disorder (MDD) | Aug 2027 |
| AstraZeneca | Glycopyrronium Muscarinic acetylcholine receptor M3 antagonist; Muscarinic acetylcholine receptor M1 antagonist; Muscarinic acetylcholine receptor inhibitor | CHRM3, CHRM1, CHRM4, CHRM2, CHRM5 | Phase 2 | Asthma | May 2029 |
| Anavex Life Sciences | ANAVEX3-71 Dual SIGMAR1 receptor agonist and M1 positive allosteric modulator | SIGMAR1, CHRM1 | Phase 2 | Schizophrenia | – |
| Brigham and Women's Hospital | Atomoxetine-plus-oxybutynin (AtoOxy) Norepinephrine reuptake inhibitor combined with muscarinic antagonist to activate pharynge | SLC6A2, CHRM1 | Phase 1 | Obstructive Sleep Apnea | Sep 2028 |
| Joshua A. Lile, Ph.D. | Cobenfy M1 muscarinic receptor agonist and 5-HT1A receptor partial agonist | HTR1A, CHRM1 | Phase 1 | Cocaine Use Disorder (CUD) | Jun 2032 |
| NSC-Therapeutics | NSC001 M1 muscarinic receptor agonist | CHRM1 | Phase 1 | Alzheimer Disease | – |
Myopia (17) Alzheimer Disease (4) Alzheimer's Disease (3) Healthy Volunteers (2) Progressive Myopia (2) Myopia, Progressive (2) Schizophrenia (2) Asthma (2) SCHIZOPHRENIA 1 (Disorder) (1) Achalasia (1) Focus on Axial Length (1) Epiphora (1)
small molecule (16)
Bristol-Myers Squibb (2) Zhaoke (Guangzhou) Ophthalmology Pharmaceutical (1) Anavex Life Sciences (1) Montefiore Medical Center (1) Ocus Innovation Ireland (1) Belfast Health and Social Care Trust (1) Oslo University Hospital (1) Joshua A. Lile, Ph.D. (1) Brigham and Women's Hospital (1) Southern College of Optometry (1) Hospital Sirio-Libanes (1) Novartis (1) AstraZeneca (1) ACADIA Pharmaceuticals (1) Sherief Abd-Elsalam (1) NSC-Therapeutics (1)
CHRM3 (9) CHRM2 (5) CHRM4 (3) SIGMAR1 (1) HTR1A (1) SLC6A2 (1) CHRM5 (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.